Exobiosphere

Exobiosphere is making pioneering strides as the world's first space-focused pre-clinical contract research organization. Their unique advantage lies in using microgravity environments to advance drug discovery, which could lead to treatments unattainable on Earth. Founded in 2024 and headquartered in Luxembourg, Exobiosphere aims to make space-based biology an integral part of the R&D pipeline.

The startup’s cutting-edge approach involves developing a standardized, space-based high-throughput testing platform. This enables the simultaneous automation of experiments in orbit and could potentially revolutionize how pharmaceutical and biotech firms approach drug development. By integrating microgravity with lab automation and bioinformatics, they achieve more relevant biological models and expedite disease progression studies.

Exobiosphere recently attracted a $1.40M early VC investment from Cedars-Sinai Technology Ventures as of 01 December 2025, underlining investor confidence in their novel solutions aimed at enhancing life both on Earth and beyond.